Acute Thrombocytopenia After Tissue Plasminogen Activator for Stroke

Area of Science:

• Neurology
• Hematology
• Pharmacology

Background:

• Stroke treatment often involves thrombolytic therapy with tissue plasminogen activator (tPA).
• Understanding potential adverse effects of tPA is crucial for patient safety.
• Early fibrinogen degradation coagulopathy (EFDC) is a known complication of tPA therapy.

Observation:

• A case of acute thrombocytopenia was observed in a patient after receiving tPA for stroke.
• Thrombocytopenia, a decrease in platelet count, was the primary observation.
• This event occurred in the context of acute ischemic stroke management.

Findings:

• This may represent the first reported instance of acute thrombocytopenia directly following tPA administration for stroke.
• The observed thrombocytopenia could potentially be part of the spectrum of EFDC associated with tPA.
• Further research is needed to confirm this association and understand its mechanisms.

Implications:

• The findings suggest a potential new adverse event associated with tPA use in stroke.
• Further studies are necessary to assess the bleeding and mortality risks in patients experiencing thrombocytopenia post-tPA.
• This highlights the importance of vigilant monitoring for hematological changes after thrombolytic therapy.